View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 6, 2021updated 11 Jul 2022 2:52pm

Sobi reports positive Phase III data of arthritis drug for Covid-19

Anakinra had a substantial efficacy in the trial and reduced disease progression and mortality risk by 64%.

Swedish Orphan Biovitrum AB (Sobi) and the Hellenic Institute for the Study of Sepsis have reported positive data from the Phase III SAVE-MORE clinical trial of anakinra plus standard of care (SOC) in moderate-to-severe Covid-19 pneumonia patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Kineret or anakinra is an interleukin-1 α and β receptor antagonist.

The drug is intended for reducing the signs and symptoms, as well as structural damage progression in moderately to severely active rheumatoid arthritis.

Conducted by the Hellenic Institute for the Study of Sepsis, Sobi funded the trial and offered the drug needed to conduct the study.

The large, pivotal, confirmatory, randomised, controlled Phase III trial enrolled 606 hospitalised Covid-19 patients at 37 trial centres in Greece and Italy.

It evaluated the efficacy and safety of early anakinra intervention guided by soluble urokinase plasminogen activator receptor (suPAR) in patients with Covid-19-associated lower respiratory tract infections (LRTI) to improve the clinical state of the disease over 28 days.

The improvement was assessed using the ordinal scale of the 11-point World Health Organization clinical progression scale.

The trial subjects were randomised into a 2:1 ratio to receive a 100mg daily subcutaneous dose of anakinra plus SOC or a placebo plus SOC for up to ten days.

Co-administered treatments included dexamethasone, anticoagulants and remdesivir.

According to data from the investigator-sponsored trial, early and targeted use of anakinra plus SOC reduced mortality risk and intensive care unit (ICU) admission.

Furthermore, the drug boosted chances of complete recovery in hospitalised Covid-19 patients with reduced prognosis due to severe respiratory failure risk.

Anakinra demonstrated substantial efficacy and lowered disease progression and mortality risk by 64% and offered a relative mortality reduction of 55% and reaching 80% for patients with a cytokine storm.

More than half of the subjects receiving the treatment recovered and the number of subjects with severe disease declined by 54%, Sobi noted.

Average time to hospital and ICU discharge was lowered by one and four days, respectively.

Sobi CEO Guido Oelkers said: “Publication of the SAVE-MORE study results in Nature Medicine demonstrates the significance of these data and further advances our understanding of the role of IL-1 in Covid-19.

“We hope to contribute to an improvement of care for patients during this critical time and welcome the opportunity to work closely with the EMA and other regulatory agencies regarding these results.”

Earlier, Sobi received a public cash offer from Advent International and GIC affiliate, Aurora Investment, valuing the company at nearly $8bn (Skr69.4bn) or $27.33 (Skr235) per share.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena